Approved research

The effect of proton pump inhibitor use on the risk of nonalcoholic fatty Liver disease, alcohol related liver disease and acetaminophen induced liver injury.

Lay summary

Purpose: 1. The primary purpose of this study is to evaluate the risks of liver diseases associated with short and long-term use of proton pump inhibitors (PPIs), focusing examine the effect of dose and type of PPIs use on the morbidity, severity and mortality of nonalcoholic fatty Liver disease, alcoholic liver disease and acetaminophen induced liver injury in short and long-term PPIs users using the data from UK biobank . 2. The second goal is using the UK biobank genetic data to find the potential mechanism of PPIs adverse reactions. 3. The last point is using the UK biobank genetic data to identify genetic variants associated with the individual susceptibility to PPIs adverse reactions, we will evaluate each genetic variant in a genome-wide fashion in the participants who were eligible for the analysis. Scientific rationale: All the required data can be found in UK biobank database. Project duration: 2020/3/1-2022/12/29 Public health impact: PPIs have revolutionized the management of acid-related diseases. There is strong evidence supporting their superior efficacy and overall safety profile. Unfortunately, this has also led to their overuse and inappropriate use. When used appropriately, the overall benefits significantly outweigh the potential risks in most patients. Almost half of all patients taking a PPI do not have a clear indication. Nearly all adverse effects associated with PPIs occur among patients who receive long-term therapy. Our research has implications for the appropriate use of PPIs. It can guide doctors proper use of PPIs in the lowest effective dose for the shortest duration possible. And our study can identify the genetic variants associated with the individual susceptibility to PPIs adverse reactions and find the potential mechanism of PPIs adverse reactions.